The massive fraudulent "science" on many levels involving the early human embryo that has been perpetrated for years has already been "institutionalized" by now in laws, regulations, textbooks, etc. We now have an additional institutionalization of it -- in a new international MEDICAL journal - i.e., Regenerative Medicine! One wonders how many "pre-embryo" advocates will flood through their doors and make their ways into its pages and its Board of Directors? And is it really a "medical" journal, or a "research" journal?
It is, indeed, only fitting for this new "medical" (read, "research") journal to be launched in Great Britain. Literally all of Great Britain's laws and regulations involving the early human embryo are explicitly and directly grounded on the false myth of the "pre-embryo" first formally articulated there in the 1985 Warnock Commission Report. How do they continue to get away with it? (See Irving, "University Faculty for Life: Submission of Concern to the British House of Lords Re the 'Human Fertilisation and Embryology (Research Purposes) Regulations 2001'"; at: http://www.lifeissues.net/writers/irv/irv_61ufl_greatbritain1.html].
If you ever doubted that the pharmaceutical industry has an enormous global and unprecedented financial interest (aka, "conflict of interests") in the very design of the protocols and the "positive" data outcomes of bench level human cloning and human embryonic stem cell research (as in so many other areas of research), doubt no more. The gross neglect of the accurate basic science and valid ethics, and the mis-management of the politics of pure bench research, are about to come to your home to roost - camouflaged as "medicine".
That pure "research" -- as contentious, convoluted, fraudulent and purely hypothetical as it is -- is about to be deconstructed into "medicine". But there is a very big difference between bench and therapeutic research and standard medical practice. Many unwitting patients still think that any "therapy" is by definition standard medical care. Not true. Only those therapies that have gone through the four phases of clinical trials (all of which by definition are still "research") and have been sanctioned by the FDA as "medicine" (rather than as "research") can be called "standard medical practice". (See Irving, "The Tragic Irony: South Korean Bioethics Committee Finds Hwang and IRBs Violated the Declaration of Helsinki" (February 2, 2006), at: http://www.lifeissues.net/writers/irv/irv_117tragicirony.html; "Biomedical research with 'decisionally incapacitated' human subjects: legalization of a defunct normative bioethics theory" (June 1998), at: http://www.lifeissues.net/writers/irv/irv_70incapacitated1.html].
What will soon be applied to you and your family as standard "medicine" will really be pure "therapeutic RESEARCH" in either global clinical trials run by the "industry", or camouflaged as "innovative therapies" to individual patients behind closed doors of the offices of private physicians. These physicians earn enormous financial bonuses for each patient they recruit for the "industry" - thus bypassing the regulations and accountability of even traditional clinical trials.
Good-bye to the Declaration of Helsinki and the Nuremberg Code, or even often loop-hole ridden national guidelines for the use of human subjects in research. The socially privileged drug "industry" -- like the scientists on their boards -- wants to privately regulate their research and be legally accountable only to itself. How to accomplish this? Reject the international ethics guidelines, reject the U.S. OPRR/OHRP federal guidelines for the use of human subjects in research - just do it behind private physicians' doors and call it standard medical "therapy". Who'd suspect?
The "free market" is one thing. This "libertine" market is truly quite another. Buyer - or patient -- beware, I suppose.
http://www.medadnews.com/News/Index.cfm?articleid=309980
PHARMA LIVE [London]
The Pulse of the PHARMACEUTICAL INDUSTRY
January 30, 2006
LONDON, Jan. 30, 2006 - Future Science Group is delighted to announce the launch of its new journal Regenerative Medicine published under the aegis of Senior Editor Dr Stephen Minger of King's College London. Regenerative Medicine provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering essential information in concise, clear and attractive article formats. The journal is published by Future Medicine, one of the Future Science Group companies.
Regenerative Medicine is published bimonthly in print and online formats and offers review articles, primary research, editorials, technology reports, interviews, perspectives and a variety of added-value content. Rigorous peer review and rapid publication ensure that only the best quality and pertinent research is published in a timely manner. The electronic version of Regenerative Medicine is available from the Future Medicine website (http://www.futuremedicine.com) and from the Ingenta aggregation service (http://www.ingentaconnect.com).
Elisa Manzotti, Editorial Director of Future Medicine commented; "In recent years we have seen substantial developments in our knowledge and understanding of stem cell biology and regenerative medicine. Nevertheless, in many respects, the field is still in its infancy. The next few decades will unveil the true potential of this emerging specialty. Regenerative Medicine will provide a critical overview of these advances as they unfold and explore their potential relevance in the clinical setting."
Senior Editor Dr Stephen Minger is Director of the Stem Cell Biology Laboratory at the Wolfson Centre for Age Related Diseases, King's College London, UK. He is assisted by an internationally acclaimed editorial advisory board comprising more than 70 leading experts.
Dr Minger commented; "The field of regenerative medicine and stem cell biology has become one of the hottest areas in contemporary science. The launch of Regenerative Medicine, as the pre-eminent, pioneering, international scientific publication in translational and cellular medicine is extremely timely." He continued, "This is the first international journal devoted to the emerging field of regenerative medicine and stem cell biology. We have assembled an outstanding group of scientists as members of the editorial board and with their help we will publish the most up-to-date research, reviews scientific and clinical meeting reports, technical updates and editorials".
Dr Minger, together with Dr Chris Mason from University College London, has also recently initiated the London Regenerative Medicine Network (LRMN). With a membership of over 1300 basic scientists, clinicians, lawyers, investors and members of the regulatory and funding bodies, monthly LRMN meetings provide highly active and collaborative symposium for current research related to regenerative medicine.
Regenerative Medicine is available now in both print and online formats. Free trial access to the first issue is available on request. Applicants should contact Stephen Galt, Sales Manager, Future Science Group at info@futuremedicine.com or visit http://www.futuremedicine.com.
For further information please contact:
Simon Boisseau, Marketing Manager, Future Science Group
T: +44 (0) 20 8349 2033 F: +44 (0) 20 8343 2313 E:
s.boisseau@futuremedicine.com
Note to editors: Free access to the launch issue of Regenerative Medicine is available. Please email info@futuremedicine.com
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain. Through its imprints, Future Medicine and Future Drugs, Future Science Group Ltd provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. For more information please access http://www.future-drugs.com and http://www.futuremedicine.com.
The first meeting of the London Regenerative Medicine Network was held on June 1st 2005. The aim of the Network is to help accelerate the progression of the world-class stem cell and tissue engineering research being undertaken in London and its translation into everyday routine clinical practice. Furthermore, the Network is aimed at helping create the positive environment required to attract and retain regenerative medicine stake-holders in the London area. The Network is a grass-roots, research-led organisation, open to all involved with the advancement of regenerative medicine including the wider scientific, clinical, engineering, commercial and regulatory community. The goal is therefore to facilitate a regular forum where all the interested parties can meet, exchange information, swap ideas and form valuable collaborations, thus all benefiting from the vast pool of talent in and around London.
Simon Boisseau
Marketing Manager
Future Science Group
Unitec House, 3rd Floor,
2 Albert Place, Finchley Central
London, N3 1QB
United Kingdom
T: +44 (0)20 8349 2033
F: +44 (0) 20 8343 2313
E: s.boisseau@future-drugs.com
http://www.future-drugs.com
http://www.futuremedicine.com
FAIR USE NOTICE: This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.